Donna Gregory, MD
Family Medicine · Cartersville, GANPI 1013987650
Payments from drug & device makers
Across 146 payments — averaging $19.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$347
- Lilly USA, LLC$325
- Novo Nordisk$289
- GSK$248
- Abbott$203
- Pfizer$167
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,814100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $347 |
| Lilly USA, LLC | 19 | $325 |
| Novo Nordisk | 16 | $289 |
| GSK | 15 | $248 |
| Abbott | 12 | $203 |
| Pfizer | 10 | $167 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Sumitomo Pharma America, Inc. | 4 | $112 |
| Shield Therapeutics Inc | 5 | $103 |
| Bayer | 5 | $102 |
| Astellas Pharma US Inc | 6 | $97 |
| Boehringer Ingelheim | 4 | $97 |
| Dexcom, Inc. | 3 | $96 |
| AstraZeneca | 5 | $69 |
| Johnson & Johnson(2 entities) | 3 | $66 |
| Amgen | 4 | $64 |
| Sanofi-aventis U.S. LLC | 2 | $52 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Radius Health, Inc. | 1 | $34 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $13 |
| Merck | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$2,814 in reported general payments places this provider in the 75th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 92 | $115,133 |
| OzempicSemaglutide | 69 | $104,403 |
| EliquisApixaban | 67 | $75,505 |
| MounjaroTirzepatide | 51 | $60,634 |
| TrulicityDulaglutide | 40 | $49,870 |
| RybelsusSemaglutide | 29 | $42,702 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $26,113 |
| JanuviaSitagliptin Phosphate | 29 | $23,667 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $22,871 |
| FarxigaDapagliflozin Propanediol | 18 | $17,859 |
| XareltoRivaroxaban | 13 | $16,557 |
| SymbicortBudesonide/Formoterol Fumarate | 37 | $14,648 |
| LinzessLinaclotide | 15 | $11,028 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,741 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $10,301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $289 | $147,10598 claims |
| Boehringer IngelheimJardiance, Tradjenta | $97 | $121,059104 claims |
| Lilly USA, LLCMounjaro, Trulicity | $325 | $110,50391 claims |
| PfizerEliquis | $167 | $75,50567 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Shingrix | $248 | $56,52989 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $69 | $43,24872 claims |
| MerckJanuvia | $12 | $23,66729 claims |
| Johnson & JohnsonXarelto | $66 | $16,55713 claims |
| AbbVieLinzess, Synthroid | $347 | $14,06050 claims |
| Sanofi-aventis U.S. LLCLantus | $52 | $2,77316 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $14 | $2,51831 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Cartersville
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.